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Corneal collagen crosslinking: from basic research to
clinical application
Abstract
Corneal collagen crosslinking is a promising new treatment of progres-
sive corneal ectasia. Its clinical use has been rapidly increasing since it was
originally introduced in 1997 as the first treatment that can improve
biomechanical stability of the weakened cornea. The method is based on the
combined action of photosensitizer riboflavin (vitamin B2) and ultraviolet
A light, which induce the formation of new covalent bonds between the col-
lagen fibers.
Our systematic search of literature in English has yielded only eight pro-
spective trials with the efficiency and safety data published to date. How-
ever, all of the published studies reveal a halt in the progression or a slight
improvement of corneal ectasia with the low complication and failure rates
after the treatment. In this review we are highlighting the method’s history,
scientific basis and its current clinical application in order to provide clini-
cians with the recent data on its benefits and potential risks.
INTRODUCTION
The term »crosslinking« refers to the formation of bonds betweensynthetic or natural polymer molecules. Collagen is the most com-
mon natural polymer and, until recently, there were only a few existing
applications of collagen crosslinking in medicine, such as bioprosthetic
heart valves (1) or formaldehyde tissue fixation (2).
Collagen crosslinks can be achieved through three basic pathways
(3). The enzymatic crosslinking of collagen fibrils occurs as a part of
their natural maturation. A prolonged exposure to monosaccharides
during aging or in diabetes mellitus can result in a non-enzymatic reac-
tion named glycation. The glycation-induced crosslinks are most likely
responsible for the protective effect of diabetes or aging on the develop-
ment and progression of keratoconus (4). Another example of collagen
crosslinking by glycation is the application of glyceraldehydes in order
to increase the corneal and scleral rigidity in tested animals (5, 6, 7).
Ozone-mediated or UV-mediated oxidation represents a third mode of
crosslinking formation (8). Since the introduction of corneal collagen
crosslinking (CXL) by Spoerl and his co-workers at Dresden Univer-
sity in Germany in 1997, the use of UV-mediated photooxidation be-
came a widely accepted new approach to strengthening the cornea
weakened by the ectatic disease or the iatrogenic intervention (5, 6).
The most common ectatic disorder is keratoconus. Keratoconus is
characterized by bilateral, mostly asymmetric, non-inflammatory and
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Overview
nical instability of the cornea. It affects approximately 1
in 2000 people and usually begins in puberty and pro-
gresses at variable rate until the patient’s mid thirties (9).
The recent advances in diagnostic devices resulted in the
detection of more subtle corneal changes, suggesting that
the subclinical forms are more common than the fully
developed keratoconus. The iatrogenic post-LASIK ecta-
sia is the second most common corneal ectasia. It usually
appears as a result of the refractive surgery performed in
predisposed individuals or in patients with an unde-
tected early form of keratoconus. Before the introduction
of CXL, the only treatment that could halt the progres-
sion of keratoconus in most cases was the transplantation
of cornea. Corneal transplantation is performed in up to
20% of keratoconus patients with the significant progres-
sion, resulting in the deterioration of their best corrected
visual acuity (10). Despite the low rate of graft failure,
corneal transplantation is still associated with the signifi-
cant risks that could result in a permanent loss of vision.
In addition, it often causes changes in patient’s lifestyle,
during and after the long period of surgical recovery.
The minimally invasive technique of corneal collagen
crosslinking improves biomechanical properties of the
ectatic corneas by forming new covalent bonds between
collagen molecules. Studies which have been conducted
so far demonstrated the beneficial effect in halting the
progression of the diseases with a very low complication
rate (11, 12).
The aim of this review is to present the new treatment
and highlight its history, scientific basis and current clin-
ical application in order to provide clinicians with the re-
cent data on the benefits and potential risks involved.
METHOD
The original crosslinking technique described by
Wollensak and co-workers is still being used today with
the minor modifications (13). The photopolymerizing
effect is induced by the combined action of riboflavin as a
photosensitizer and long wavelength ultraviolet (UVA)
light of 370 nm. This particular wavelength was chosen
so that riboflavin can achieve a maximal absorption while
still remaining bellow harmful radiation levels. During
the exposure, riboflavin is excited into a triplet state gen-
erating the so called reactive oxygen species which in
turn induce the formation of new covalent bonds be-
tween the amino acids of neighboring collagen fibers (4).
The treatment is performed in sterile environment.
After a local anesthetic had been applied, lid speculum is
inserted and a central corneal abrasion up to 9.0 mm in
diameter is made for a better diffusion of riboflavin into
the stroma. According to the protocol of the Institute for
Refractive and Ophthalmic Surgery in Zurich, Switzer-
land, 0.1% riboflavin solution containing 10 mg of riblo-
flavin-5-phosphate diluted in 10 mL of 20% dextran so-
lution is instilled every 3 minutes for 30 minutes. After
that, central corneal thickness is measured by an ultra-
sound pachymetry device. For safety reasons, additional
riboflavin 0.1% hypoosmotic drops without dextran should
be applied in corneas whose thickness is less than 400 mm.
Otherwise, UVA light should not be applied. Also, eyes
are inspected with the slit lamp to ensure that riboflavin
has penetrated into the anterior chamber of the eye. The
cornea is then irradiated for 30 minutes with an UVA il-
lumination device. The device must provide a homoge-
nous UV radiation with irradiance of 3 mW/cm2 at the
working distance of 5 cm. During irradiation, the cornea
is moistened every 3 minutes with the riboflavin 0.1%
drops. The total dosage delivered to the cornea in that
way is 5.4 J/cm2. At the end of the procedure antibiotic
ointment is applied and bandage lens inserted to facili-
tate the epithelial healing. After the healing is complete,
the patients are instructed to use steroid drops in order to
prevent haze formation.
The modifications of the standard protocol include
the use of a 9 mm marker, shorter initial riboflavin appli-
cation and the optional Pilocarpine 1% preoperative use
in Sienna protocol (14, 33), working distances of up to 10
cm (15, 16) or the less efficient transepithelial (C3-R)
crosslinking that could be utilized in cases of thin cornea
(12, 17, 18).
The effect of CXL on the corneal
biomechanics
The human cornea has 5 layers. Only two corneal lay-
ers, Bowman’s layer and stroma, contain collagen fibrils.
While Bowman’s layer is only 8 to 10 mm thick, stroma
accounts for up to 90% of the corneal thickness and is re-
sponsible for the most of the cornea’s tensile strength (19,
20). Collagen fibrils form bundles which are woven into
three to five hundred equidistant lamellae that run from
limbus to limbus. Collagen lamellae are inserted into a
network of dendriform keratocyte cells which are respon-
sible for the development and the maintenance of the
stromal structure. The more oblique interweaving and
branching of bundles and lamellae occurs in anterior and
peripheral stroma. The interweaving and branching, to-
gether with the circumferential orientation of fibrils in
the peripheral stroma, (21) could be one of the reasons
why only very few pathological changes in cases of ectatic
diseases, like keratoconus, occur near the corneal limbus
(19).
Because of the very complex 3-dimensional structure
of the cornea, it is necessary to reduce it to a linear and di-
rectionally uniform system in order to perform compara-
ble calculations. Thus, changes in the biomechanical
properties of the cornea can be assessed through more re-
liable and comparable parameters, like Young’s modulus
of elasticity. Young’s modulus is usually experimentally
determined during the from the slope of the stress-strain
curve.
In the ectatic diseases like keratoconus, the tensile
strength of the cornea is reduced by about 36% (22). On
the other hand, the stress-strain measurements of the hu-
man corneas treated with CXL showed an increase in
biomechanical rigidity by up to 329%, as well as an in-
crease in Young’s modulus by the factor of 4.5 (23) This
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increase is much more significant than the increase in
the crosslinked animal models (23, 24). The reduced
biomechanical effect in rabbits’ corneas is explained by
the higher degree of baseline cross-linking. The reason
for the lesser effect in porcine corneas could be a signifi-
cantly higher average corneal thickness. Namely, the main
effect of CXL is observed in the anterior 242 mm of the
cornea, with the maximum depth of approximately 350 mm
(24, 25). Therefore, in porcine corneas, with the average
thickness of approximately 850 mm, the crosslinked ante-
rior section is counterbalanced by the larger posterior
stroma where no crosslinks were formed.
It has also been shown that the collagen fibril diame-
ter in the treated portion of rabbits’ corneas was increased
by 12.2%, probably due to the molecular spacing of the
crosslinked collagen (26). The long-term effects of CXL
in rabbits showed a significant and variable increase in
the stress measurements which remained stable over the
8 month period. The increase of 79% in Young’s modulus
remained unchanged when measured immediately after,
one month and 8 months after the treatment (24).
Clinical efficacy and safety
The first prospective, nonrandomized clinical pilot
study on humans was published by the Dresden research
group in 2003 (13). The study included 23 eyes of 22 pa-
tients with the moderate or advanced progressive kerato-
conus. The progression of keratoconus was halted in all
treated eyes. Regression was detected in 70% of the eyes,
with the reduction of the maximal keratometry readings
by 2.01 diopters and of the refractive error by 1.14 diop-
ters. There was a slight improvement in the visual acuity
in 65% of the eyes. No adverse reactions were noted.
Since then, eight prospective studies were published.
Four prospective studies included less than 30 eyes with a
follow-up period of 4 to 12 months (27, 28, 29, 30). All
four studies reported varying degrees of improvement
and a very good safety profile. The preliminary results of
the first randomized prospective clinical trial of 66 eyes of
49 Australian patients treated with CXL were also favor-
able (31). In more than half of the treated eyes a notable
reduction in maximal keratometry readings was noted
after one year. While there was no statistically significant
improvement in the best corrected visual acuity, a posi-
tive trend was observed. A degree of postoperative haze,
which resolved during the follow-up, was noticed in all
treated patients. There were no vision-threatening com-
plications and no significant changes in the endothelial
cell density. The investigators have indicated a relatively
poor reproducibility of the visual acuity, subjective re-
fraction and scanning-slit topography. The scanning-slit
topographers, like the Orbscan device used in their study,
were shown to have a lower repeatability and reprodu-
cibility than the rotating Scheimpflug cameras (32).
The scanning-slit topography also showed some un-
derestimation of the corneal thickness compared to the
ultrasound and OCT pachymetry during the first 3
months after the CXL in the Italian non-randomized
prospective trial. The authors attribute the difference in
Orbscan pachymetry measurements to the presence of a
demarcation line between the treated and the untreated
stroma. Other studies have observed a decrease in the
number of keratocytes in the treated anterior and inter-
mediate stroma, in front of the demarcation line, during
the first two to three months after which the repopula-
tion by activated keratocytes took place (25,16). The
2-year results of the Italian study showed the stability of
44 keratoconic eyes and the improvement in the best cor-
rected visual acuity without any relevant side effects (33).
The researchers in the other two prospective studies
used the Scheimpflug cameras for corneal measurements
(11, 34). Along with the Scheimpflug measurements, the
Indian researchers also used the optical coherence to-
mography in order to obtain more reproducible results.
They have found no change in the best corrected visual
acuity and the corneal curvatures 1 year after crosslink-
ing was made, thus indicating a halt in keratoconus pro-
gression. The study has also shown no lens and macula
changes after the UVA exposure.
The Swiss prospective study of a large group of 117
eyes with primary ectasia evaluated the complication
and failure rates after CXL with a 1-year follow-up (11).
The complication rate, defined as a percentage of eyes
loosing two or more lines on the Snellen visual acuity
chart, was 2.9%. The identified risk factors for visual loss
were age over 35 years and the best spectacle-corrected
visual acuity of 20/25 or better. With the established up-
per age-limit of 35 years, the complication rate in their
study dropped to 1.04%. The failure rate, defined as the
percentage of eyes with continued progression, was 7.6%.
The only identified risk factor for failure in this study was
a maximal corneal curvature greater than 58.00 diopters.
For the eyes bellow that limit, the failure rate was 2.8%.
The failure rate reported in most other studies is even
lower, ranging between 0 to 1%. More information is ex-
pected from the nine FDA approved phase II, III and IV
trials on the crosslinking treatment, which are at the mo-
ment being conducted in the United States.
Regarding the use of corneal collagen crosslinking in
patients with iatrogenic ectasia, a small series of ten pa-
tients who developed a post-LASIK ectasia was pub-
lished (15). The follow-up demonstrated a halt or partial
improvement of keratectasia in all patients after treat-
ment.
Despite the fact that no sight-threatening complica-
tions were recorded in the large prospective studies, there
are some sporadic reports in that regard in the literature.
In two cases, a stromal haze resistant to topical steroid
treatment appeared 2 to 3 months after the CXL. The
best corrected visual acuity improved despite the haze
(36). Kymionis and co-workers reported one case of a dif-
fuse lamellar keratitis after the corneal crosslinking was
performed in a patient with the post-LASIK ectasia (37).
He also reported a case of herpetic keratitis and iritis in-
duced by the CXL treatment which responded well to
the therapy (38). An unfortunate case of Acanthamoeba
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keratitis with corneal perforation in a patient who was re-
peatedly rinsing his face with tap water, unaware that he
was wearing a bandage contact lens, was also reported
(39). In this patient a therapeutic keratoplasty was per-
formed. Several other reports of microbial keratitis in
CXL patients were also reported (40, 41). The patient
treated in Sydney acquired a severe keratitis after clean-
ing his bandage contact lens in his mouth before putting
it back in his eye treated with CXL (41).
Final remarks
In recent years, corneal collagen crosslinking has be-
come a standard treatment for the progressive corneal
ectasia in numerous centers throughout the world. Addi-
tional basic and clinical research is necessary in order to
establish more precise indications and to demonstrate
the permanence of the treatment. The reliable data on
the turnover rate of the collagen fibers are still insuffi-
cient due to the almost complete absence of corneal re-
modeling (24). However, data such as the increased re-
sistance to the enzymatic degradation in the crosslinked
corneas, support the theory of the long-lasting effect of
the treatment (42).
Other potential indications for the collagen crosslink-
ing treatment are being investigated. There are several
reports on the use of CXL in patients with the bullous
keratopathy and the corneal ulcers resistant to conserva-
tive therapy (43, 44). Collagen crosslinking of sclera us-
ing riboflavin and UVA or glyceraldehyde was suggested
as a potential treatment for progressive myopia (7).
Despite the evidence in support of the safety of new
procedure, future studies are necessary to define its limi-
tations and its long-term efficacy. Every deviation from
the standard technique can cause irreversible damage to
the corneal endothelium or other eye structures (45).
Until a more complete list of indications and contraindi-
cations is established, this useful procedure should be
performed only by the well informed surgeons that can
identify and diminish all the potential risks.
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